AlloVir, Inc. (ALVR) |
|
4.45 -0.43 (-8.81%)
|
03-22 11:31 |
|
Open: |
4.86 |
Pre. Close: |
4.88 |
|
High:
|
4.86 |
Low:
|
4.45 |
|
Volume:
|
51,714 |
Market Cap:
|
416(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:14:06 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 6.97 One year: 8.45 |
| Support: |
Support1: 3.92 Support2: 3.26 |
| Resistance: |
Resistance1: 5.97 Resistance2: 7.23 |
| Pivot: |
5.14 |
| Moving Average: |
MA(5): 4.67 MA(20): 5.53
MA(100): 6.23 MA(250): 6.12 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 27.3  %D(3): 19.3 |
| RSI: |
RSI(14): 35.6 |
| 52-week: |
High: 10.28 Low: 3.17 |
| Average Vol(K): |
3-Month: 272 (K) 10-Days: 318 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALVR ] has closed above bottom band by 24.4%. Bollinger Bands are 11% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.95 - 4.97 |
4.97 - 5 |
|
Low:
|
4.59 - 4.61 |
4.61 - 4.63 |
|
Close:
|
4.84 - 4.87 |
4.87 - 4.91 |
|
Company Description |
|
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. |
Headline News |
Mon, 20 Mar 2023
Allovir Inc (ALVR) Stock: What Does the Chart Say Monday? - InvestorsObserver
Tue, 07 Mar 2023
MetLife Investment Management LLC acquires new AlloVir, Inc ... - Best Stocks
Wed, 15 Feb 2023
Why AlloVir (ALVR) Stock Is Falling Today - AlloVir (NASDAQ:ALVR) - Benzinga
Wed, 15 Feb 2023
AlloVir GAAP EPS of -$2.20 beats by $0.05 (NASDAQ:ALVR) - Seeking Alpha
Wed, 01 Feb 2023
AlloVir to Participate in the SVB Securities Global Biopharma ... - Business Wire
Wed, 25 Jan 2023
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
93 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
49.8 (%) |
|
% Held by Institutions
|
40.6 (%) |
|
Shares Short
|
5,420 (K) |
|
Shares Short P.Month
|
4,250 (K) |
Stock Financials |
|
EPS
|
-2.14 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.47 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-38 |
|
Return on Equity (ttm)
|
-75.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.83 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-142 (M) |
|
Levered Free Cash Flow
|
-83 (M) |
Stock Valuations |
|
PE Ratio
|
-2.15 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.85 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
